Solantey - not sure you are aware of another company that is potentially involved with AMBS called ARYC. This is a company that has the microarray technology platform and they've developed a pre-symptomatic test (PDx) which can foretell 25 years in advance your potential for developing Parkinson's, and is 100% accurate. These two companies met back in January, and we know that AMBS dissolved their JV with another pharma recently. ARYC has also developed a pre-symptomatic ovarian cancer test which looks 5 years into the future called OvaDx. There could easily be a collaboration announced between AMBS and ARYC with their two technologies, one to screen and one to treat (MANF). ARYC's pps is .20¢ and AMBS is .09¢
Read the recent SeekingAlpha article by bio-tech analyst Jason Napadano. He believes the current valuation to be three times the current share price without attributing any value to Amarantus Diagnostic.